High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013

Actavis’ branded pharmaceuticals business has an industry-leading pipeline of product opportunities focused on ensuring sustainable growth in each therapeutic category.

Our pipeline is driven by key opportunities within the core therapeutic areas of Women’s Health and Urology, as well as Dermatology and Gastroenterology products. We also have a portfolio of five biosimilar products under development in Women’s Health and Oncology therapeutic categories.

Actavis focuses its business development efforts on finding new opportunities to invest in and adding additional products to the pipeline.

Actavis’ R&D strategy focuses on the following product development areas:

  • The application of proprietary drug-delivery technology for new product development in specialty areas
  • The acquisition of mid-to-late development-stage brand drugs and biosimilars

Our near-term product development pipeline includes:

  • A second generation progesterone vaginal gel for infertility
  • Esmya™ in the U.S. for long-term uterine sparing
  • Two novel long-acting contraceptives in late stage development
  • A topical antibiotic for the treatment of bacterial vaginosis

With the acquisition of Warner Chilcott in October 2013, we significantly expanded our Women’s Health pipeline with the addition of seven pipeline programs, two products late stage development and 12 products in Phase III or the marketing application phase of development.

The combination also added three mid-to-late phase Urology products in development and additional Dermatology and Gastroenterology products in various stages of development.